Larimar Therapeutics (LRMR) Notes Payables (2014 - 2020)

Larimar Therapeutics' Notes Payables history runs 7 years deep, the most recent figure standing at $7.3 million for Q1 2020.

• Quarterly Notes Payables changed 0.0% year-over-year to $7.3 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $7.3 million (changed 0.0% YoY) and the FY2019 annual result came in at $7.3 million, up 33.33% from the prior year.
• Notes Payables was $7.3 million for Q1 2020 at Larimar Therapeutics, roughly flat from $7.3 million in the prior quarter.
• Across five years, Notes Payables topped out at $7.3 million in Q1 2019 and bottomed at $1.3 million in Q3 2017.
• A 5-year average of $4.4 million and a median of $3.6 million in 2016 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2017 — Notes Payables tumbled 59.35% — and 2019, when it surged 300.06%.
• Larimar Therapeutics' Notes Payables stood at $3.6 million in 2016, then slumped by 64.67% to $1.3 million in 2017, then jumped by 330.21% to $5.5 million in 2018, then jumped by 33.33% to $7.3 million in 2019, then changed by 0.0% to $7.3 million in 2020.
• Business Quant data shows LRMR's Notes Payables at $7.3 million in Q1 2020, $7.3 million in Q4 2019, and $7.3 million in Q3 2019.